J&J provides early hope for single-dose Covid-19 vaccine
Pivotal data for JNJ-78436735 are imminent, with Novavax and Curevac not far behind.
J&J pause adds to adenovirus vaccine doubts
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Covid vaccine developers face nervous wait
More details on an adverse event in a trial of Astrazeneca's AZD1222 will be needed to assess the fallout for other vaccine developers.
Moderna reminds the markets of biotech’s dual purpose
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
